Curation EIEE1 ARX

Gene ARX
Disease EIEE1
Inheritance XR
Score

11.5 + 5 = 16.5 / 18

Genetic + experimental = total
Classification
0
18
Refuted
Moderate
Definitive
Last Updated 08/18/2025
Pubs Reviewed 6
Publication Span 13.33 years
Publication Interval 13.33 years
Curator(s) Macayla Weiner, Laurel Hiatt
Description

ARX-related early infantile epileptic encephalopathy/West syndrome is supported by X-linked familial linkage and multiple reports of ARX polyalanine repeat expansions, especially the first polyalanine tract expansion c.333_334ins(GCG)7 / pA1 expansion from 16 to 23 alanines and recurrent exon 2 polyalanine expansions associated with infantile spasms, hypsarrhythmia, developmental delay/intellectual disability, dystonia, and related epileptic encephalopathy phenotypes. Experimental support includes an Arx(GCG)10+7 knock-in mouse model recapitulating infantile spasm-like events, seizures, EEG abnormalities, behavioral impairment, and interneuron deficits, with additional gene-level ARX developmental studies supporting a role in interneuron migration and forebrain development.

Genetic evidence

Total: 11.5

Category
Type
Citation
Score
Details
Singular Evidence
Probands
6

Screened 98 unrelated patients with intellectual disability plus infantile epilepsy and/or hand dystonia; ARX polyalanine expansions were identified in four familial cases, including c.333_334ins(GCG)7 in a male with severe intellectual disability, West syndrome, spasticity, dystonia, dyskinesia, and affected relatives.

Singular Evidence
Probands
3

Two unrelated X-linked infantile spasms/West syndrome families with multiple affected males showing infantile spasms or seizures, hypsarrhythmia, and severe/profound developmental impairment; the study mapped the disease interval to Xp11.4-Xpter before ARX was identified, so this is linkage-level rather than ARX repeat-specific proband evidence.

Singular Evidence
Probands

One of eight patients with sporadic cryptogenic West syndrome carried a de novo hemizygous ARX exon 2 c.441_464dup 24-bp duplication expanding the second polyalanine tract from 12 to 20 alanines; the paper also notes prior reports of the same mutation in 57 patients from 12 families.

Collective Evidence
Segregation
1.5

In two X-linked infantile spasms families, markers DXS336, DXS333, DXS389, and DMD43 were completely linked with disease; combined linkage gave maximal LOD 2.357 for DXS989 and DMD49 at recombination fraction 0.0 and multipoint LOD 2.36 across Xpter-Xp11.4. This predates ARX identification and is not repeat-specific.

Collective Evidence
Allele
1

ARX polyalanine expansion size/location was associated with phenotype: the first tract expansion from 16 to 23 alanines ((GCG)10+7) was reported in ISSX/West syndrome families, while a second tract expansion from 12 to 20 alanines occurred across X-linked MR/epilepsy/Partington phenotypes; expansions were absent from >300 control chromosomes.

Experimental evidence

Total: 5

Category
Type
Citation
Score
Details
Models
Non-human model organism
2

PMID:19587282 generated a viable Arx(GCG)10+7 knock-in mouse model matching the human first polyalanine tract expansion, with infantile spasm-like myoclonus, persistent seizures/EEG abnormalities, cognitive and behavioral impairment, and reduced calbindin/NPY/cholinergic interneuron populations. PMID:11889467 provides gene-level mouse/zebrafish ortholog expression context, not an independent disease model.

Models
Non-human model organism
2

The phenotypes exhibited in the mutant mice match those of patients with infantile spasms. The mice also develop partial seizures early in life that evolve into different seizure types and persist into adulthood as in humans.

Function
Biochemical function
0.5

Gene-level evidence: ARX encodes a paired-class homeodomain transcription factor with conserved homeodomain, OAR/aristaless domain, and octapeptide motif speculated to mediate transcriptional repression; the study does not directly test repeat-specific biochemical function.

Function
Regulatory impact
0.5

The repeat may modulate epigenetic silencing (X inactivation) in symptomatic individuals.

Maximum score caps apply at evidence type, category, and supercategory levels, so section totals may be lower than the raw sum of row scores.